Analyst Price Targets — NPCE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 23, 2026 10:04 am | — | Mizuho Securities | $22.00 | $14.58 | TheFly | NeuroPace initiated with an Outperform at Mizuho |
| May 15, 2026 4:57 pm | — | H.C. Wainwright | $20.00 | $15.09 | TheFly | NeuroPace price target raised to $20 from $19 at H.C. Wainwright |
| January 27, 2026 11:04 am | — | H.C. Wainwright | $19.00 | $16.23 | TheFly | NeuroPace price target raised to $19 from $18 at H.C. Wainwright |
| December 16, 2025 12:49 pm | — | UBS | $22.00 | $15.93 | TheFly | NeuroPace price target raised to $22 from $18 at UBS |
| December 9, 2025 12:58 pm | Priya Sachdeva | UBS | $18.00 | $16.37 | StreetInsider | UBS Reiterates Buy Rating on NeuroPace Inc (NPCE) Post NAUTILUS Trial Results |
| November 5, 2025 11:20 am | Mike Kratky | Leerink Partners | $19.00 | $9.40 | StreetInsider | NeuroPace Inc (NPCE) PT Raised to $19 at Leerink Partners |
| November 5, 2025 11:04 am | Ross Osborn | Cantor Fitzgerald | $16.00 | $9.40 | StreetInsider | Cantor Fitzgerald Says NeuroPace Inc (NPCE) Remains a Top Pick |
| August 14, 2024 6:30 am | Vik Chopra | Wells Fargo | $15.00 | $7.28 | TheFly | NeuroPace price target lowered to $15 from $20 at Wells Fargo |
| May 23, 2024 8:44 am | Frank Takkinen | Lake Street | $20.00 | $7.99 | TheFly | NeuroPace post Q1 move 'overdone,' says Lake Street |
| March 14, 2024 5:08 am | Larry Biegelsen | Wells Fargo | $20.00 | $13.63 | StreetInsider | Wells Fargo Upgrades NeuroPace Inc (NPCE) to Overweight |
Latest News for NPCE
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming 2026 Cantor Global Healthcare Conference. NeuroPace management will participate in a fireside chat discussion on Wednesday, September 9 at 10:55am EDT, and host one-on-one meetings…
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference. NeuroPace management will participate in a fireside chat discussion on Tuesday, September 8 at 8:00am EDT, and host one-on-one meetings…
NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.
NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuation, liquidity and regulatory risks warrant patience.
NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regulatory path after the FDA setback.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NPCE.
U.S. House Trading
No House trades found for NPCE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.